Home > Urology > EAU 2019 > Prostate Cancer > Prostate cancer active surveillance: Better patient risk stratification and use of imaging

Prostate cancer active surveillance: Better patient risk stratification and use of imaging

Presented By
Dr Todd Morgan, Dr Vasilis Stavrinides, Dr Marco Bandini
Conference
EAU 2019
Appears to be safe to expand indication for active surveillance (AS) to Gleason 3+4, but the data on using MRI instead of biopsy in AS are not yet clear. The 6 Movember Global Action Plan (GAP) consortia are worldwide collaborations between researchers in prostate and testicular cancer tackling questions of unmet needs: biomarkers (GAP1), imaging (GAP2), active surveillance (AS, GAP3), exercise and metabolic health (GAP4), testicular cancer (GAP5), and oligometastatic prostate cancer (GAP6). At EAU19, the Movember GAP3 consortium (Dr Todd Morgan, University of Michigan at Ann Arbor, USA presenting for Hellman et al.) reported on 7,704 men being followed by AS from 14 centres: 6,725 men with Grade Group (GG)1 3+3 disease (87%) and 979 men with GG2 3+4 disease (13%). Discontinuation of AS (40% GG1 vs 50% GG2) was attributable to: switch to active treatment due to progression (19% vs 23%), switch to acti...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on